Merck & Co.: Generic COVID pill manufacturing
October 27, 2021
US pharmaceutical company Merck & Co. announced on Wednesday a deal with the UN-backed Medicines Patent Pool (MPP), which would allow more companies to manufacture generic versions of its COVID-19 pill.
The licensing agreement will help millions of people in poorer countries access molnupiravir, the company's antiviral medication developed with Ridgeback Biotherapeutics.
What is the deal about?
Under the agreement, Merck & Co., which trades under the name MSD outside the United States and Canada, grants a license to MPP which can then sub-license to manufacturers of generic drugs.
MPP is a Geneva-based international organization backed by the UN that works to facilitate the development of medicines for low- and middle-income nations.
The royalty-free license would apply to 105 such countries.
This means that Merck & Co. will not receive sales royalties while COVID-19 remains classified as a public health emergency of international concern (PHEIC) by the World Health Organization.
"This is the first transparent, public health-driven voluntary license for a COVID-19 medical technology," Merck & Co. and MPP said in a joint statement.
What is the antiviral pill?
Molnupiravir, an experimental oral antiviral pill, has been found to reduce the risk of serious disease and death by 50% when given within days of a positive test, according to phase three clinical trials.
No deaths were reported in patients who received the pill, while eight deaths had been recorded in patients who received a placebo.
"The interim results for molnupiravir are compelling and we see this oral treatment candidate as a potentially important tool to help address the current health crisis," said MPP executive director Charles Gore.
The US Food and Drug Administration and the European Medicines Agency are already reviewing the drug, and a decision could come within weeks.
Earlier this year, US-based Merck & Co. signed bilateral licensing deals with eight Indian generic drug makers, including Cipla, Dr. Reddy's Labs, and Sun Pharmaceuticals, among others.
"We all along knew that we would want to diversify the geographic footprint of our generic partners so that we did not only have generic suppliers in India but in other geographies as well," Paul Schaper, executive director of the pharmaceutical company's global public policy, told Reuters news agency.
adi/wd (Reuters, AFP)